Investigation of a truncated cardiac troponin T that causes familial hypertrophic cardiomyopathy: Ca(2+) regulatory properties of reconstituted thin filaments depend on the ratio of mutant to wild-type protein.

Familial hypertrophic cardiomyopathy (HCM) is caused by mutations in at least 8 contractile protein genes, most commonly beta myosin heavy chain, myosin binding protein C, and cardiac troponin T. Affected individuals are heterozygous for a particular mutation, and most evidence suggests that the mutant protein acts in a dominant-negative fashion. To investigate the functional properties of a truncated troponin T shown to cause HCM, both wild-type and mutant human cardiac troponin T were overexpressed in Escherichia coli, purified, and combined with human cardiac troponins I and C to reconstitute human cardiac troponin. Significant differences were found between the regulatory properties of wild-type and mutant troponin in vitro, as follows. (1) In actin-tropomyosin-activated myosin ATPase assays at pCa 9, wild-type troponin caused 80% inhibition of ATPase, whereas the mutant complex gave negligible inhibition. (2) Similarly, in the in vitro motility assay, mutant troponin failed to decrease both the proportion of actin-tropomyosin filaments motile and the velocity of motile filaments at pCa 9. (3) At pCa 5, the addition of mutant complex caused a greater increase (21.7%) in velocity of actin-tropomyosin filaments than wild-type troponin (12.3%). These data suggest that the truncated troponin T prevents switching off of the thin filament at low Ca(2+). However, the study of thin filaments containing varying ratios of wild-type and mutant troponin T at low Ca(2+) indicated an opposite effect of mutant troponin, causing enhancement of the inhibitory effect of wild-type complex, when it is present in a low ratio (10% to 50%). These multiple effects need to be taken into account to explain the physiological consequences of this mutation in HCM. Further, these findings underscore the importance of studying mixed mutant:wild-type preparations to faithfully model this autosomal-dominant disease.

[1]  D. Szczesna,et al.  Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. , 2001, The Journal of biological chemistry.

[2]  J. Seidman,et al.  Altered regulatory function of two familial hypertrophic cardiomyopathy troponin T mutants. , 1999, Biochemistry.

[3]  E. Homsher,et al.  Functional Consequences of Troponin T Mutations Found in Hypertrophic Cardiomyopathy* , 1999, The Journal of Biological Chemistry.

[4]  H. Watkins,et al.  Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. , 1999, Cardiovascular Research.

[5]  Steven B Marston,et al.  Functional analysis of human cardiac troponin by the in vitro motility assay: comparison of adult, foetal and failing hearts. , 1999, Cardiovascular research.

[6]  A. Børglum,et al.  α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy , 1999 .

[7]  H. Watkins,et al.  Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  B. Hainque,et al.  Familial hypertrophic cardiomyopathy: from mutations to functional defects. , 1998, Circulation research.

[9]  T. Hewett,et al.  A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.

[10]  B. Malnic,et al.  Regulatory Properties of the NH2- and COOH-terminal Domains of Troponin T , 1998, The Journal of Biological Chemistry.

[11]  B. Maron,et al.  A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. , 1998, Circulation research.

[12]  I. Fraser,et al.  Troponin I and troponin T interact with troponin C to produce different Ca2+-dependent effects on actin-tropomyosin filament motility. , 1997, The Biochemical journal.

[13]  H. Watkins,et al.  Effects of two hypertrophic cardiomyopathy mutations in alpha-tropomyosin, Asp175Asn and Glu180Gly, on Ca2+ regulation of thin filament motility. , 1997, Biochemical and biophysical research communications.

[14]  P. Jha,et al.  Interaction of deletion mutants of troponins I and T: COOH-terminal truncation of troponin T abolishes troponin I binding and reduces Ca2+ sensitivity of the reconstituted regulatory system. , 1996, Biochemistry.

[15]  J. Seidman,et al.  Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action. , 1996, The Journal of clinical investigation.

[16]  E. Homsher,et al.  Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. , 1996, The Journal of clinical investigation.

[17]  M. Geeves,et al.  Separation and characterization of the two functional regions of troponin involved in muscle thin filament regulation. , 1995, Biochemistry.

[18]  J. Seidman,et al.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.

[19]  I. Fraser,et al.  In Vitro Motility Analysis of Actin-Tropomyosin Regulation by Troponin and Calcium , 1995, The Journal of Biological Chemistry.

[20]  J. Potter,et al.  A Direct Regulatory Role for Troponin T and a Dual Role for Troponin C in the Ca2+ Regulation of Muscle Contraction (*) , 1995, The Journal of Biological Chemistry.

[21]  S. Minchin,et al.  Overexpression of human cardiac troponin-I and troponin-C in Escherichia coli and their purification and characterisation. Two point mutations allow high-level expression of troponin-I. , 1994, European journal of biochemistry.

[22]  Christine E. Seidman,et al.  α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere , 1994, Cell.

[23]  L. Leinwand,et al.  Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. , 1994, The Journal of biological chemistry.

[24]  M. Way,et al.  Expression of human plasma gelsolin in Escherichia coli and dissection of actin binding sites by segmental deletion mutagenesis , 1989, The Journal of cell biology.

[25]  L. Smillie,et al.  Effects of troponin-I plus-C on the binding of troponin-T and its fragments to alpha-tropomyosin. Ca2+ sensitivity and cooperativity. , 1983, The Journal of biological chemistry.

[26]  S. Perry.  The regulation of contractile activity in muscle. , 1979, Biochemical Society transactions.

[27]  H. S. Kim,et al.  Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. , 1999, The Journal of clinical investigation.

[28]  H. Watkins,et al.  Functional effects of hypertrophic cardiomyopathy mutations in alpha-tropomyosin on Ca2+ regulation of thm filaments , 1998 .

[29]  F. Studier,et al.  Use of T7 RNA polymerase to direct expression of cloned genes. , 1990, Methods in enzymology.